Home › Dermatomyositis › California
Dermatomyositis clinical trials in California
9 studies for Dermatomyositis are looking for participants at sites in California.
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Research Site, Irvine
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 24, 2026 · NCT06455449Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of California Irvine - Accepting Adult Patients, Orange
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients, San Francisco
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, La Jolla
- Research Site, Sacramento
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 15, 2026 · NCT06916806A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- 200 UCLA Medical Plaza, Los Angeles
- UCLA Clinical & Translational Research Center (CTRC), Los Angeles
- UCLA, Los Angeles
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT05895786A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 2, 2026 · NCT07800871Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- University of California-Irvine, Orange
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Jul 22, 2026 · NCT06371417Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
- Stanford University, Palo Alto
- Stanford University, Stanford
RecruitingPhase 1
Ages 25 to 72 · All sexes · Updated May 21, 2025 · NCT06298019From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.